Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Flygt H, Söderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, Mustjoki S, Dimitrijevic A, Stentoft J, Majeed W, Roy L, Wolf D, Dreimane A, Gjertsen BT, Gedde-Dahl T, Ahlstrand E, Markevärn B, Hjorth-Hansen H, Janssen J, Olsson-Strömberg U. Flygt H, et al. Among authors: dreimane a. Leukemia. 2024 Apr;38(4):925. doi: 10.1038/s41375-024-02184-z. Leukemia. 2024. PMID: 38418611 Free PMC article. No abstract available.
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.
Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Höglund M, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Gruber FX, Stenke L, Eriksson KM, Markevärn B, Lübking A, Vestergaard H, Udby L, Bjerrum OW, Persson I, Mustjoki S, Olsson-Strömberg U. Hjorth-Hansen H, et al. Among authors: dreimane a. Leukemia. 2016 Sep;30(9):1853-60. doi: 10.1038/leu.2016.121. Epub 2016 May 2. Leukemia. 2016. PMID: 27133821 Clinical Trial.
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S, Höglund M, Markevärn B, Själander A, Lotfi K, Dreimane A, Lübking A, Holm E, Björeman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S. Ilander M, et al. Among authors: dreimane a. Leukemia. 2017 May;31(5):1108-1116. doi: 10.1038/leu.2016.360. Epub 2016 Nov 28. Leukemia. 2017. PMID: 27890936 Free PMC article. Clinical Trial.
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Flygt H, Söderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, Mustjoki S, Dimitrijevic A, Stentoft J, Majeed W, Roy L, Wolf D, Dreimane A, Gjertsen BT, Gedde-Dahl T, Ahlstrand E, Markevärn B, Hjorth-Hansen H, Janssen J, Olsson-Strömberg U. Flygt H, et al. Among authors: dreimane a. Leukemia. 2024 Apr;38(4):781-787. doi: 10.1038/s41375-024-02145-6. Epub 2024 Jan 26. Leukemia. 2024. PMID: 38278960 Free PMC article.
Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?
Richter J, Söderlund S, Lübking A, Dreimane A, Lotfi K, Markevärn B, Själander A, Saussele S, Olsson-Strömberg U, Stenke L. Richter J, et al. Among authors: dreimane a. J Clin Oncol. 2014 Sep 1;32(25):2821-3. doi: 10.1200/JCO.2014.55.6910. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071107 No abstract available.
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Höglund M, Koskenvesa P, Lotfi K, Majeed W, Markevärn B, Ohm L, Olsson-Strömberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J; Nordic CML Study Group. Hjorth-Hansen H, et al. Among authors: dreimane a. Eur J Haematol. 2015 Mar;94(3):243-50. doi: 10.1111/ejh.12423. Epub 2014 Sep 13. Eur J Haematol. 2015. PMID: 25082346 Free PMC article. Clinical Trial.
No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.
Gunnarsson N, Höglund M, Stenke L, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A. Gunnarsson N, et al. Among authors: dreimane a. Leukemia. 2017 Aug;31(8):1825-1827. doi: 10.1038/leu.2017.131. Epub 2017 May 2. Leukemia. 2017. PMID: 28461694 Free article. No abstract available.
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
Flygt H, Söderlund S, Stentoft J, Richter J, Koskenvesa P, Mustjoki S, Majeed W, Lübking A, Dreimane A, Markevärn B, Stenke L, Myhr Eriksson K, Gjertsen BT, Gedde-Dahl T, Dimitrijevic A, Udby L, Olsson-Strömberg U, Hjorth-Hansen H. Flygt H, et al. Among authors: dreimane a. Eur J Haematol. 2021 Dec;107(6):617-623. doi: 10.1111/ejh.13699. Epub 2021 Aug 31. Eur J Haematol. 2021. PMID: 34418168 Free article.
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
Huuhtanen J, Ilander M, Yadav B, Dufva OM, Lähteenmäki H, Kasanen T, Klievink J, Olsson-Strömberg U, Stentoft J, Richter J, Koskenvesa P, Höglund M, Söderlund S, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Stenke L, Myhr-Eriksson K, Markevärn B, Lübking A, Dimitrijevic A, Udby L, Bjerrum OW, Hjorth-Hansen H, Mustjoki S. Huuhtanen J, et al. Among authors: dreimane a. J Clin Invest. 2022 Sep 1;132(17):e152585. doi: 10.1172/JCI152585. J Clin Invest. 2022. PMID: 36047494 Free PMC article.
22 results